A randomized, open label, phase II study of prophylactic octreotide (OCT) to prevent/reduce the frequency and severity of diarrhea in patients (pts) receiving lapatinib (LAP) with capecitabine (CAP) for the treatment of metastatic breast cancer (mBC)Petr Krivorotko, Alexey Manikhas, Stephen Chan et al.|Annals of Oncology|2018Cited by 0